FGFR2 and neoplasm: As shown in Fig. 7C, primary human T-ALL cells with HS-5 were injected subcutaneously and BGJ398 or PBS was intraperitoneal injected every 2 days for a total of seven times, the growth of tumours in mice with FGF2 and FGFR2 blockade was slower than control mice (p < 0.05).